Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits.

GlobeNewsWire • Feb 10, 2026

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz

GlobeNewsWire • Dec 26, 2025

Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

GlobeNewsWire • Dec 22, 2025

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly.

GlobeNewsWire • Dec 18, 2025

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company.

GlobeNewsWire • Oct 30, 2025

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial,” in the International Wound Journal . Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. Celularity's Chairman and CEO, Robert J. Hariri, M.D., Ph.D., also commented on PDA-002 as a stem cell therapy which qualifies under a recently enacted Florida law expanding access in the state to stem cell therapies not yet approved by the U.S. Food and Drug Administration.

GlobeNewsWire • Oct 14, 2025

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan. Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).

GlobeNewsWire • Sep 3, 2025

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.

GlobeNewsWire • Aug 22, 2025

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V.

GlobeNewsWire • Aug 18, 2025

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into a strategic partnership with Fountain Life, a global leader in science-backed longevity and preventative health company, to supply stem cell therapy products manufactured and distributed by Celularity.

GlobeNewsWire • Jul 9, 2025